# lung adenocarcinoma (LUAD) - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 22652
- Completion tokens: 9420
- Reasoning tokens: 0
- Total tokens: 32072
- API requests reported: 2
- Elapsed seconds: 89.915
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: DeepSeek

---
# Multidimensional Interpretation of Prognostic Transcriptomic Results in Lung Adenocarcinoma (LUAD)

## Critical Data-Quality Warning (Read First)

Before any biological interpretation, the statistical input must be flagged as **technically suspicious**:

- **96 of 100 selected genes are risk-associated (HR > 1); only 4 are protective (HR < 1)**. This extreme imbalance is not typical of a well-calibrated survival screen.
- **Hazard ratios of 5.185e+21, 1.929e-22, and P = 0 / FDR = 0** are numerically degenerate. HRs of 10²¹ and P values of exactly 0 are not biologically interpretable effect sizes; they indicate **quasi-complete separation** or a model-fitting artifact (e.g., a Cox model where a predictor perfectly separates events from censoring, or near-zero variance in a subgroup).
- **A large fraction of the extreme-HR genes are pseudogenes, pseudogene-like loci, unannotated loci, lncRNAs, and Y-linked or testis-specific transcripts** (e.g., RBMY1F, RBMY2AP, TTTY4C, FAM9A, TEX13A, RNY1P3, MTND1P1, multiple RP11/CTD/AC/LOC loci). These are often **lowly expressed or absent in most samples**, and their HRs are driven by a handful of outliers or zero-inflation.
- The ledger flags `Y_RNA` as `direction-conflict; rows=163`, meaning multiple rows for the same gene disagree in direction — a further sign of unstable estimates.

**Consequence:** The direct statistical evidence from this table cannot be used to claim that any individual gene is a validated prognostic biomarker. The analysis below therefore (a) states this limitation explicitly, and (b) proceeds with a clearly labeled **exploratory interpretation** using the biologically interpretable genes in the table (those with finite, moderate HRs), external annotations, and literature, while marking all program-level conclusions as hypotheses rather than established findings.

---

## 1. Overall Biological Interpretation

Setting aside the degenerate HRs, the biologically interpretable portion of the table (HRs roughly 0.7–1.5 with FDR < 0.001) points to a **coherent set of risk-associated signals** rather than a random assortment:

- **Wnt/developmental signaling**: DKK1 (HR=1.475), TLE1 (HR=1.484), PITX3 (HR=1.429), VAX1 (HR=1.335) are all connected to Wnt/β-catenin or developmental transcriptional programs. The batch-level GO/KEGG query also returned "Regulation of Wnt signaling pathway" (GO:0030111), "Positive regulation of Wnt signaling, planar cell polarity pathway" (GO:2000096), and KEGG "Wnt signaling pathway" as recurrent modules.
- **Glycosylation / cell-surface remodeling**: FUT4 (HR=1.403), B3GNT3 and B4GALT1 (network partners of FUT4), and RHCG (HR=1.29) suggest altered fucosylation and glycosphingolipid biosynthesis (KEGG module retrieved: "Mannose type O-glycan biosynthesis," "Glycosphingolipid biosynthesis").
- **Cytoskeletal / Rho-GTPase signaling**: RHOF (HR=1.403) with STRING partners ACTN1 and ARHGAP1, plus RGS20 (HR=1.352) with G-protein partners GNAZ/GNB5/GNAI2/GNAQ, point to actin reorganization, migration, and GPCR-coupled signaling.
- **Keratinization / squamous-like plasticity**: KRT6A (HR=1.39) is a classical stress keratin; its appearance in LUAD tumor tissue may reflect either tumor-cell plasticity or contamination from adjacent squamous/basal epithelium or stroma.
- **Protective signals** are few and isolated: RBMXP1 (HR=0.2118), CRNDE (HR=0.716), CMAHP (HR=0.7055). These are single-gene signals with no shared program, and RBMXP1 is a pseudogene.

**Overall theme:** The interpretable risk signal is dominated by a **developmental/Wnt–glycosylation–Rho/actin–keratinization axis** that, if real, would be consistent with a more aggressive, dedifferentiated, or mesenchymal-like LUAD phenotype. However, the extreme HRs and the dominance of pseudogenes/lncRNAs in the risk group mean that the **statistical backbone of this conclusion is fragile** and needs independent validation.

---

## 2. Core Biological Programs (≤5)

| # | Program | Direction | Major Supporting Genes | Standardized Pathway | Why These Genes Together | Evidence Strength / Limitations |
|---|---------|-----------|------------------------|----------------------|---------------------------|--------------------------------|
| 1 | **Wnt/β-catenin and developmental transcriptional signaling** | Risk-associated (HR>1) | DKK1 (1.475), TLE1 (1.484), PITX3 (1.429), VAX1 (1.335) | KEGG: Wnt signaling pathway; GO:0030111 (regulation of Wnt signaling) | DKK1 is a canonical Wnt inhibitor whose overexpression in tumors often reflects feedback activation of the pathway; TLE1 is a corepressor of Wnt/TCF targets; PITX3 and VAX1 are developmental transcription factors that can intersect Wnt and differentiation programs. Collectively they suggest aberrant reactivation of developmental signaling in aggressive LUAD. | **Moderate biological plausibility, weak statistical robustness.** Four independent genes support the program, but DKK1 and TLE1 are also individually associated with LUAD prognosis in the literature, so part of the signal may reflect known biology rather than a novel discovery. No independent-cohort statistic is available. |
| 2 | **Glycosylation / cell-surface fucosylation** | Risk-associated | FUT4 (1.403), RHCG (1.29), network partners B3GNT3, B4GALT1 | KEGG: Mannose type O-glycan biosynthesis; Glycosphingolipid biosynthesis | FUT4 encodes α1,3-fucosyltransferase, which modifies Lewis antigens and integrins; B3GNT3 and B4GALT1 are glycosyltransferases that can cooperate with FUT4 in glycan chain extension. RHCG is an ammonia transporter but is used here as a cell-surface marker gene. Altered fucosylation is a known feature of tumor immune evasion and metastasis. | **Moderate.** FUT4's LUAD relevance is supported by prior literature, but RHCG's inclusion is weaker (it is not a glycosyltransferase). The batch-level KEGG query returned glycosylation modules, but these are not formal enrichment statistics from the uploaded cohort. |
| 3 | **Rho-GTPase / actin cytoskeleton signaling** | Risk-associated | RHOF (1.403), RGS20 (1.352) | GO: regulation of actin cytoskeleton organization; GO: cell migration | RHOF is a Rho-family GTPase with STRING links to ACTN1 (actin-binding) and ARHGAP1 (RhoGAP); RGS20 is a regulator of G-protein signaling with STRING links to GNAZ/GNB5/GNAI2/GNAQ. Together they point to cytoskeletal remodeling, migration, and GPCR-coupled signaling — features of invasive tumors. | **Moderate.** Two independent genes with network support, but the network evidence is from STRING (predicted/curated interactions, not necessarily direct physical binding in LUAD). No formal enrichment was computed on the uploaded cohort. |
| 4 | **Keratinization / squamous-like plasticity** | Risk-associated | KRT6A (1.39) | GO: keratinization; Hallmark: Epithelial–Mesenchymal Transition (contextual) | KRT6A is a stress-inducible keratin. In LUAD, its expression can reflect either tumor-cell plasticity toward a squamous/basal-like state or contamination from adjacent non-tumor epithelium. | **Weak-to-moderate.** Single-gene support. The direction (risk) is consistent with aggressive behavior, but the cell-of-origin ambiguity is a major confounder. |
| 5 | **Long non-coding RNA / pseudogene risk signature** | Risk-associated | LINC01312 (1.364), LINC02178 (1.297), LINC01910 (1.312), LINC02323 (1.373), LINC02802 (1.333), ITGB1-DT (1.302), FAS-AS1 (HR=5.185e+21), plus ~40 RP11/CTD/AC/LOC loci | No single standardized pathway; the program is defined by locus class rather than function | The sheer number of lncRNAs/pseudogenes in the risk group suggests that the risk signal may be driven by **technical artifacts** (low expression, zero-inflation, multi-mapping reads) rather than a coherent biological program. However, some lncRNAs (e.g., ITGB1-DT, FAS-AS1) have documented roles in cancer. | **Weak as a biological program, strong as a technical red flag.** This program should be treated primarily as a **data-quality concern** until validated by orthogonal methods (qPCR, RNA-seq with better annotation, or single-cell data). |

---

## 3. Key Genes and Interaction Modules (≤10)

| # | Gene / Module | Direction (HR) | Role in Core Programs | Proposed Relationship | Relationship Type |
|----------------|----------------|----------------|----------------------|----------------------|-------------------|
| 1 | **DKK1** | Risk (1.475) | Wnt signaling | DKK1 is a secreted Wnt inhibitor; its overexpression can reflect feedback activation of Wnt/β-catenin. | Pathway co-membership (Wnt pathway); no direct physical interaction claimed |
| 2 | **TLE1** | Risk (1.484) | Wnt signaling / transcriptional repression | TLE1 is a corepressor that can interact with TCF/LEF transcription factors. | Regulatory interaction (transcriptional corepressor); direct physical interaction with TCF/LEF is documented in the literature but not in this dataset |
| 3 | **PITX3 + VAX1** | Both risk (1.429, 1.335) | Developmental transcription factors | Both are homeodomain transcription factors; they may co-regulate developmental programs but no direct interaction is known. | Co-expression / pathway co-membership (developmental transcription); indirect or putative relationship |
| 4 | **FUT4 + B3GNT3 + B4GALT1** | FUT4 risk (1.403); B3GNT3/B4GALT1 are STRING partners | Glycosylation | FUT4 adds fucose; B3GNT3 and B4GALT1 extend glycan chains; they can act in the same biosynthetic pathway. | Pathway co-membership (glycan biosynthesis); STRING links are predicted/curated, not necessarily direct physical binding |
| 5 | **RHOF + ACTN1 + ARHGAP1** | RHOF risk (1.403) | Rho/actin signaling | RHOF is a Rho GTPase; ACTN1 is an actin-crosslinking protein; ARHGAP1 is a RhoGAP. STRING lists RHOF–ACTN1 and RHOF–ARHGAP1 as interactions. | Predicted/curated protein interaction (STRING); not confirmed as direct physical binding in LUAD |
| 6 | **RGS20 + GNAZ/GNB5/GNAI2/GNAQ** | RGS20 risk (1.352) | GPCR / G-protein signaling | RGS20 is a GTPase-activating protein for Gα subunits; STRING lists high-confidence interactions with GNAZ (0.952), GNB5 (0.947), GNAI2 (0.820), GNAQ (0.803). | Predicted/curated protein interaction (STRING); RGS20's role as a GAP for Gαz is documented, so a functional regulatory interaction is plausible |
| 7 | **KRT6A** | Risk (1.39) | Keratinization / squamous plasticity | No clear interaction partners in this dataset. | Standalone gene; no interaction claimed |
| 8 | **ITGB1-DT** | Risk (1.302) | lncRNA module | ITGB1-DT is an antisense lncRNA to ITGB1 (integrin β1); literature (PMID 34906142) suggests an ITGB1-DT/ARNTL2 axis in LUAD. | Regulatory interaction (antisense lncRNA, literature-supported); not confirmed by this dataset's statistics |
| 9 | **RBMXP1** | Protective (0.2118) | None (pseudogene) | RBMXP1 is a pseudogene; the protective direction is likely a technical artifact (near-zero expression in most samples). | No biological program claimed |
| 10 | **CRNDE** | Protective (0.716) | None (lncRNA) | CRNDE is a known oncogenic lncRNA in several cancers, but here it is protective. This direction is **counter to prior literature** and should be treated as a potential artifact or cohort-specific effect. | Standalone gene; direction conflict with literature is explicitly noted |

**Interaction evidence caveat:** All STRING links above are **predicted or curated protein interactions**, not direct physical binding confirmed in LUAD tissue. Do not interpret co-expression, pathway co-membership, or STRING links as evidence of direct physical interaction.

---

## 4. Validation Priorities (≤5)

| # | Direction | Why Prioritize | Current Dataset Evidence | External Evidence | Next Step | Conclusion Status |
|---|-----------|----------------|--------------------------|-------------------|-----------|-------------------|
| 1 | **Confounding / composition check** | The extreme HRs (10²¹) and the dominance of pseudogenes/lncRNAs suggest technical artifacts or cell-composition effects, not biology. | 96/100 genes risk-associated; HRs of 5.185e+21 and P=0; `Y_RNA` has direction-conflicting rows. | None needed — this is an internal data-quality issue. | Re-run survival analysis with (a) expression filtering (e.g., remove genes with <10% nonzero expression), (b) adjustment for tumor purity (e.g., ESTIMATE or CIBERSORT), (c) penalized Cox or Firth's correction for separation. | **Established evidence** (data-quality flag) |
| 2 | **Mechanistic hypothesis: Wnt signaling** | DKK1, TLE1, PITX3, VAX1 form a coherent risk program. | HRs 1.335–1.484, FDR < 2.5e-5. | Wnt pathway is a well-studied driver in LUAD; DKK1 is a known Wnt inhibitor with prognostic associations. | Use LUAD cell lines or patient-derived organoids to knock down DKK1/TLE1 and assess β-catenin activity, proliferation, and migration. | **Exploratory hypothesis** (no independent-cohort statistic provided) |
| 3 | **Biomarker: FUT4 / glycosylation** | FUT4 is a druggable glycosyltransferase with a clear mechanistic link to metastasis. | FUT4 HR=1.403, FDR=2.935e-4. | FUT4 is implicated in tumor immune evasion and metastasis in several cancers. | Validate FUT4 protein expression by IHC in an independent LUAD cohort; test whether FUT4 expression correlates with Lewis antigen (sLeX) levels. | **Exploratory hypothesis** |
| 4 | **Therapeutic target: RHOF / Rho-GTPase** | RHOF has STRING links to actin regulators and a literature association with worse survival in AML (PMID 34405015). | RHOF HR=1.403, FDR=3.997e-4. | RHOF is a less-studied Rho GTPase; its role in LUAD is not established. | Test RHOF knockdown in LUAD cell lines; assess migration/invasion in vitro. | **Exploratory hypothesis** |
| 5 | **Interaction / network hypothesis: RGS20–G-protein module** | RGS20 has high-confidence STRING interactions with GNAZ/GNB5/GNAI2/GNAQ and a clear functional role as a GAP. | RGS20 HR=1.352, FDR=5.793e-4. | RGS20 is known to regulate Gαz signaling; its role in LUAD prognosis is not established. | Co-immunoprecipitation to confirm RGS20–GNAZ binding in LUAD cells; assess GPCR pathway activity. | **Exploratory hypothesis** |

**Note on therapeutic claims:** The existence of drugs targeting Wnt, glycosylation, or Rho pathways does not constitute evidence that these are effective LUAD targets. No drug-efficacy data are present in this dataset.

---

## 5. Evidence Grounding

| Conclusion | Direct Input Evidence | Pathway/Ontology Evidence | Protein/Regulatory Evidence | Disease-Association Evidence | Literature Evidence | Independence Assessment |
|------------|----------------------|---------------------------|-----------------------------|------------------------------|---------------------|--------------------------|
| Wnt risk program (DKK1/TLE1/PITX3/VAX1) | HRs 1.335–1.484, FDR < 2.5e-5 | Batch-level GO/KEGG returned Wnt modules | TLE1's corepressor role is documented | DKK1/TLE1 have prior LUAD associations | PMID 34906142 (ITGB1-DT/ARNTL2), PMID 34405015 (RHOF) | Partially independent: the batch-level GO/KEGG query and the literature may share the same underlying publications; the uploaded HRs are the only direct cohort evidence |
| Glycosylation (FUT4/B3GNT3/B4GALT1) | FUT4 HR=1.403 | Batch-level KEGG returned glycan biosynthesis modules | STRING links FUT4–B3GNT3, FUT4–B4GALT1 | FUT4 has cancer associations | Literature supports FUT4 in metastasis | The GO/KEGG and STRING annotations may derive from the same curated databases; not fully independent |
| Rho/actin (RHOF/RGS20) | RHOF HR=1.403; RGS20 HR=1.352 | GO annotations for actin organization and GTPase activity | STRING links RHOF–ACTN1, RHOF–ARHGAP1, RGS20–GNAZ | RHOF has AML survival association (PMID 34405015) | PMID 34405015 | STRING and GO annotations overlap in underlying literature; not fully independent |
| Keratinization (KRT6A) | KRT6A HR=1.39 | GO: keratinization | None | KRT6A has cancer associations | PMID 42216026 (KRT6A in alopecia, not LUAD) | Weak; single gene, no LUAD-specific literature retrieved |
| lncRNA/pseudogene risk module | ~40 risk-associated lncRNA/pseudogene loci | None | None | None | None | **Insufficient evidence** for a biological program; likely technical artifact |

**External statistical validation was not performed.** No independent-cohort statistic (HR, P, or FDR) was supplied for any gene in this dataset. Pathway recurrence, STRING links, and literature support are contextual evidence only and do not constitute replication.

---

## 6. Limitations and Alternative Explanations (≤5)

1. **Technical artifact / quasi-complete separation.** HRs of 10²¹, P=0, and the extreme imbalance (96 risk vs. 4 protective) are hallmarks of model-fitting failure. This is the single most important limitation. **How to investigate:** re-fit Cox models with Firth's penalized likelihood, filter low-expression genes, and use bootstrap to assess stability of HR estimates.

2. **Tumor purity and cell-composition effects.** KRT6A (keratin) and numerous lncRNAs/pseudogenes could reflect contamination from adjacent squamous epithelium, stroma, or immune cells rather than tumor-cell biology. **How to investigate:** use ESTIMATE/CIBERSORTx to estimate purity and cell fractions; validate KRT6A by IHC to determine whether it is expressed in tumor cells or stroma.

3. **Disease severity / stage confounding.** The dataset is from LUAD tumor tissue but no stage, grade, or treatment information is provided. If the risk genes correlate with stage, the HRs may reflect disease severity rather than independent prognostic value. **How to investigate:** adjust for stage, age, sex, and smoking status in a multivariable Cox model.

4. **Batch / platform effects and annotation gaps.** Many genes are labeled `UNMAPPED_ENSEMBL` or are poorly annotated RP11/CTD/AC/LOC loci. Multi-mapping reads and outdated annotations can produce spurious HRs. **How to investigate:** remap reads to the latest reference annotation; collapse multi-mapping reads; use a stricter expression threshold.

5. **Association-versus-causation ambiguity.** Even if the moderate-HR genes are replicated, their expression changes in bulk tumor tissue do not establish whether they drive tumor progression or merely correlate with it. **How to investigate:** functional perturbation experiments (e.g., CRISPR knockdown in LUAD cell lines) and single-cell RNA-seq to determine which cell types express the risk genes.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=23, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
